Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Autolus TherapeuticsSQZ BiotechnologiesAptose BiosciencesOutlook TherapeuticsInnate Pharma
SymbolNASDAQ:AUTLNYSE:SQZNASDAQ:APTONASDAQ:OTLKNASDAQ:IPHA
Price Information
Current Price$5.30$12.46$5.03$1.76$4.40
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.31.71.41.61.1
Analysis Score3.43.53.53.53.1
Community Score2.44.32.72.82.2
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.81.70.0
Earnings & Valuation Score0.60.60.00.00.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$21.71$38.33$11.63$6.33$8.25
% Upside from Price Target309.70% upside207.65% upside131.11% upside259.85% upside87.50% upside
Trade Information
Market Cap$276.91 million$353.95 million$454.86 million$315.96 million$347.56 million
Beta1.75N/A1.620.46N/A
Average Volume756,222168,2823,838,5744,252,81537,641
Sales & Book Value
Annual Revenue$2.91 millionN/AN/A$8.15 million$96.12 million
Price / Sales95.34N/AN/A37.493.62
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$5.67 per shareN/A$1.23 per share$0.02 per share$3.18 per share
Price / Book0.93N/AN/A88.001.38
Profitability
Net Income$-123,850,000.00N/A$-26,280,000.00$-35,240,000.00$-23,250,000.00
EPS($2.88)N/A($0.52)($0.67)($0.34)
Trailing P/E RatioN/A0.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-8,652.90%N/AN/AN/AN/A
Return on Equity (ROE)-54.01%N/A-49.53%N/AN/A
Return on Assets (ROA)-44.19%N/A-46.65%-148.04%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/A0.33%0.08%
Current Ratio7.43%N/A24.60%1.13%1.99%
Quick Ratio7.43%N/A24.60%1.13%N/A
Ownership Information
Institutional Ownership Percentage22.86%N/A52.22%3.04%2.13%
Insider Ownership PercentageN/AN/A6.30%4.00%N/A
Miscellaneous
Employees376101318247
Shares Outstanding52.35 million27.87 million88.84 million173.61 million78.99 million
Next Earnings Date5/6/2021 (Estimated)6/17/2021 (Estimated)5/4/2021 (Estimated)5/21/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableOptionableNot OptionableNot Optionable
SourceHeadline
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF APRIL 1, 2021NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF APRIL 1, 2021
finance.yahoo.com - April 19 at 5:32 AM
SVB Leerink Comments on Innate Pharma S.A.s FY2021 Earnings (NASDAQ:IPHA)SVB Leerink Comments on Innate Pharma S.A.'s FY2021 Earnings (NASDAQ:IPHA)
americanbankingnews.com - April 9 at 8:37 AM
SVB Leerink Equities Analysts Reduce Earnings Estimates for Innate Pharma S.A. (NASDAQ:IPHA)SVB Leerink Equities Analysts Reduce Earnings Estimates for Innate Pharma S.A. (NASDAQ:IPHA)
americanbankingnews.com - April 8 at 8:14 AM
Innate Pharma S.A. (NASDAQ:IPHA) Short Interest Up 53.1% in MarchInnate Pharma S.A. (NASDAQ:IPHA) Short Interest Up 53.1% in March
americanbankingnews.com - March 31 at 2:36 PM
SVB Leerink Raises Innate Pharma (NASDAQ:IPHA) Price Target to $7.00SVB Leerink Raises Innate Pharma (NASDAQ:IPHA) Price Target to $7.00
americanbankingnews.com - March 25 at 9:00 AM
Number of shares and voting rights of Innate Pharma as of February 1, 2021Number of shares and voting rights of Innate Pharma as of February 1, 2021
finance.yahoo.com - February 24 at 1:16 AM
Investigation announced for Investors in shares of Innate Pharma S.A. (NASDAQ: IPHA) over potential WrongdoingInvestigation announced for Investors in shares of Innate Pharma S.A. (NASDAQ: IPHA) over potential Wrongdoing
openpr.com - February 11 at 2:37 PM
Innate Pharma advances lacutamab clinical development programInnate Pharma advances lacutamab clinical development program
finance.yahoo.com - February 9 at 1:07 AM
Innate Pharma: Attractive Price, But Comes With UncertaintyInnate Pharma: Attractive Price, But Comes With Uncertainty
seekingalpha.com - January 30 at 11:51 PM
Innate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for DevelopmentInnate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for Development
apnews.com - January 6 at 8:57 AM
IPHA Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Innate Pharma S.A. Investors of Class Action and Lead PlaintiffIPHA Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Innate Pharma S.A. Investors of Class Action and Lead Plaintiff
bloomberg.com - December 23 at 2:09 PM
IPHA Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Innate Pharma S.A. Investors of Class Action and Lead Plaintiff Deadline: December 22, 2020IPHA Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Innate Pharma S.A. Investors of Class Action and Lead Plaintiff Deadline: December 22, 2020
businesswire.com - December 21 at 12:25 PM
FINAL DEADLINE THIS WEEK: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmFINAL DEADLINE THIS WEEK: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - December 20 at 3:12 PM
IPHA Deadline Alert: Rosen, A Trusted and Top Ranked Law Firm, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action - IPHAIPHA Deadline Alert: Rosen, A Trusted and Top Ranked Law Firm, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action - IPHA
finance.yahoo.com - December 19 at 5:30 PM
DEC. 22 DEADLINE: Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of ...DEC. 22 DEADLINE: Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of ...
apnews.com - December 19 at 7:29 AM
IPHA LOSS ALERT: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Innate Pharma S.A. Investors to Seek Counsel Before  Important December 22 Deadline in Securities Class Action – IPHAIPHA LOSS ALERT: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Innate Pharma S.A. Investors to Seek Counsel Before Important December 22 Deadline in Securities Class Action – IPHA
finance.yahoo.com - December 18 at 9:28 PM
DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Innate Pharma S.A. and Encourages Investors to Contact the FirmDEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Innate Pharma S.A. and Encourages Investors to Contact the Firm
finance.yahoo.com - December 18 at 9:28 PM
DEC. 22 DEADLINE: Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action – IPHADEC. 22 DEADLINE: Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action – IPHA
benzinga.com - December 18 at 4:28 PM
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Innate Pharma SA (IPHA)
finance.yahoo.com - December 18 at 11:27 AM
ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action - IPHAROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Reminds Innate Pharma S.A. Investors of Important December 22 Deadline in Securities Class Action - IPHA
finance.yahoo.com - December 15 at 8:19 PM
Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action – IPHAZhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action – IPHA
benzinga.com - December 13 at 12:12 AM
Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action - IPHAZhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action - IPHA
marketwatch.com - December 11 at 6:49 PM
SHAREHOLDER DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmSHAREHOLDER DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Innate Pharma S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
finance.yahoo.com - December 11 at 6:49 PM
Zhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action – IPHAZhang Investor Law Reminds Innate Pharma S.A. Investors with Losses of December 22 Deadline in Securities Class Action – IPHA
finance.yahoo.com - December 11 at 1:48 PM
Innate To Return US & EU Commercialization Rights Of Lumoxiti To AstraZeneca - Quick FactsInnate To Return US & EU Commercialization Rights Of Lumoxiti To AstraZeneca - Quick Facts
nasdaq.com - December 11 at 3:48 AM
DateCompanyBrokerageAction
3/16/2021Autolus TherapeuticsRedburn PartnersReiterated Rating
1/29/2021Autolus TherapeuticsJPMorgan Chase & Co.Downgrade
1/7/2021Autolus TherapeuticsTruistLower Price Target
1/7/2021Autolus TherapeuticsHC WainwrightLower Price Target
1/6/2021Autolus TherapeuticsMizuhoReiterated Rating
12/8/2020Autolus TherapeuticsNeedham & Company LLCReiterated Rating
9/23/2020Autolus TherapeuticsWilliam BlairReiterated Rating
7/22/2020Autolus TherapeuticsSunTrust BanksInitiated Coverage
6/17/2020Autolus TherapeuticsJefferies Financial GroupReiterated Rating
3/30/2021SQZ BiotechnologiesBrookline Capital ManagementReiterated Rating
1/7/2021SQZ BiotechnologiesEvercore ISIInitiated Coverage
11/24/2020SQZ BiotechnologiesStifel NicolausInitiated Coverage
11/24/2020SQZ BiotechnologiesBank of AmericaInitiated Coverage
11/24/2020SQZ BiotechnologiesBTIG ResearchInitiated Coverage
3/30/2021Aptose BiosciencesOppenheimerBoost Price Target
2/22/2021Aptose BiosciencesJonestradingInitiated Coverage
10/20/2020Aptose BiosciencesCanaccord GenuityReiterated Rating
10/19/2020Aptose BiosciencesCantor FitzgeraldInitiated Coverage
9/22/2020Aptose BiosciencesAlliance Global PartnersInitiated Coverage
6/23/2020Aptose BiosciencesPiper SandlerReiterated Rating
6/12/2020Aptose BiosciencesMaxim GroupInitiated Coverage
5/23/2019Aptose BiosciencesRoth CapitalReiterated Rating
3/1/2019Aptose BiosciencesRoyal Bank of CanadaInitiated Coverage
1/25/2019Aptose BiosciencesCitigroupInitiated Coverage
2/17/2021Outlook TherapeuticsLADENBURG THALM/SH SHReiterated Rating
5/16/2019Outlook TherapeuticsCIBCInitiated Coverage
4/22/2019Outlook TherapeuticsAscendiant Capital MarketsInitiated Coverage
3/25/2021Innate PharmaSVB LeerinkBoost Price Target
11/23/2020Innate PharmaThe Goldman Sachs GroupInitiated Coverage
9/9/2020Innate PharmaBryan, Garnier & CoDowngrade
(Data available from 4/19/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.